He coordinates the H2020 project REPO-TRIAL on in-silico network pharmacology and the organ-agnostic European drug repurposing platform project REPO4EU. Eventually, how we practice medicine and conduct biomedical research will radically change.īio: Harald is a physician scientist (MD/PhD) and pharmacist (PharmD) in systems medicine to re-define what we call “disease” from a descriptive symptom- and organ-based to a mechanism-based approach and rapid repurposing of registered drugs for new clinical applications by network pharmacology. Precise and effective therapeutic intervention is subsequently achieved by synergistic multi-compound network pharmacology, ideally through drug repurposing, obviating the need for drug discovery, and speeding up the clinical translation. Such modules often contain several fragments of several different canonical pathways. These modules are however distinct from classical pathways, which we now recognize to be not more than highly curated mind maps of signaling events. Descriptive disease phenotypes are replaced by mechanistic endotypes defined by causal, multi-target signaling modules that also explain respective comorbidities. Systems medicine’s therapeutic arm, network pharmacology, revolutionizes how we define, diagnose, treat, and ideally cure diseases. Systems Medicine overcomes this roadblock by re-integrating the human body in an evidence-based manner enabled by data science and bioinformatics. The biggest conceptual error in Medicine was to split up the human body organ by organ, including organ-specific research disciplines and to pretend one can define a disease within one organ. “Rethinking signaling and disease to make an impact for medicine and patients”Ībstract: We do not understand the causality of almost any human disease and thus can only chronically alleviate symptoms, which is highly ineffective and imprecise.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |